Evidence map›Paper›PMID 36416495›Full record

ArticleNeuro-oncology2023

Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma.

Benjamin Lin, Julia Ziebro, Erin Smithberger, Kasey R Skinner, Eva Zhao, Timothy F Cloughesy, Zev A Binder, Donald M O'Rourke, David A Nathanson, Frank B Furnari and 1 more

Open access · bronzeAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Benjamin LinDepartment of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Julia ZiebroDepartment of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Erin SmithbergerDepartment of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Kasey R SkinnerDepartment of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Eva ZhaoDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Zev A BinderDepartment of Neurosurgery and Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Donald M O'RourkeDepartment of Neurosurgery and Glioblastoma Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David A NathansonDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Frank B FurnariDepartment of Medicine, Division of Regenerative Medicine, University of California, San Diego, San Diego, California, USA.
C Ryan MillerDepartment of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
University of Alabama at Birmingham · USUniversity of California, Los Angeles · USUniversity of Pennsylvania · USUniversity of California, San Diego · USUniversity of North Carolina at Chapel Hill · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANG LI · 2017 to 2026
$25.2M
Genotypic Interactions in Brain Cancer HeterogeneityR01NS080939 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FURNARI, FRANK · 2012 to 2022
$3.5M
Credentialing next-generation human glioma models for precision therapeuticsR01CA258248 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Frank Furnari, Christopher Ryan Miller · 2022 to 2026
$3.0M
CDKN2A couples lipid metabolism to ferroptosis in glioblastomaR01NS121319 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENSINGER, STEVEN J, DIXON, SCOTT · 2021 to 2025
$2.5M
Genotypic Interactions in Brain Cancer HeterogeneityR56NS080939 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FURNARI, FRANK · 2023 to 2023
$537k
The role of a histone point mutation in pediatric gliomagenesisF31CA247177 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SKINNER, KASEY R · 2020 to 2022
$121k
NCI NIH HHS F31 CA247177NCI NIH HHS P50 CA211015NINDS NIH HHS R01 NS080939NINDS NIH HHS R01NS121319NINDS NIH HHS R56 NS080939
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36416495
PMCPMC9825333
OpenAlexW4309791443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.